Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
  • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
  • A61K40/22—Immunosuppressive or immunotolerising
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/418—Antigens related to induction of tolerance to non-self
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4747—Apoptosis related proteins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
  • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
  • C12N5/0648—Splenocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/515—Animal cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
  • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
  • C12N2501/20—Cytokines; Chemokines
  • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
  • C12N2501/20—Cytokines; Chemokines
  • C12N2501/23—Interleukins [IL]
  • C12N2501/2313—Interleukin-13 (IL-13)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
  • C12N2501/20—Cytokines; Chemokines
  • C12N2501/24—Interferons [IFN]

Definitions

• This disclosure describes, in one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD).
• the method includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject.
• MDSCs myeloid-derived suppressor cells
• the method includes a plurality of serial administrations of MDSCs as previously-administered MDSCs experience inflammasome activation.
• At least a portion of the plurality of MDSCs comprises a genetic modification causing the MDSC to resist inflammasome activation.
• the method includes co-administering to the subject an agent that inhibits inflammasome activation.
• this disclosure describes a method of treating a tumor in a subject.
• the method includes administering to the subject an anti -tumor therapy and co- administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
• FIG. 1 Bone marrow derived MDSC-IL13 enhance GvHD survival, but suppression is compromised after five days in vivo.
• (A) Lethally irradiated BALB/c recipients were given 1 x 10 7 C57B1/6 bone marrow (BM only), or bone marrow plus 2 x 10 6 CD25-depleted T cells (GvHD) or bone marrow, T cells and 6 x 10 6 MDSC-IL13 (GvHD+MDSC-IL13) as indicated.
• B-C Surface expression of congenic (CD45.2 + ) MDSC-IL13 recovered from spleens five days after transfer to irradiated animals receiving bone marrow only (no GvHD) or bone marrow plus T cells (GvHD). Data represents three replicates per group with p ⁇ 0.001 for all markers shown.
• D Representative histograms indicating responding T cell proliferation as denoted by CFSE dilution.
• FIG. 2 Inflammasome activity evident in recovered MDSCs.
• A Western blot of cell ly sates from recovered wild-type or ASC _/" MDSC-IL13 probed for active plO form of caspase-1 and ⁇ -actin.
• ImageJ software was used to convert to grayscale, straighten and crop gel image to highlight lanes of interest according to size.
• B Caspase-1 plO blot quantification relative to ⁇ - actin, GvHD vs all other groups, p ⁇ 0.05. Quantification was carried out on scanned blots by densitometric analysis from ImageJ software (NIH)
• C IL- ⁇ ELISA of supernatants after day 5 recovered MDSC-IL13 were plated in complete RPMI media overnight, GvHD vs all other groups, p ⁇ 0.05. Dotted line indicates limit of ELISA detection. All data are representative of two independent experiments.
• FIG. 3 In vitro inflammasome induction in MDSC leads to loss of suppressor function
• Inflammasome induction in freshly cultured wild-type and ASC _/" MDSC-IL13 was carried out by adding 0.2 ⁇ g/ml LPS for three hours, followed by addition of 2 mM ATP or 0.8 ⁇ g/ml poly(dT) transfection.
• A Culture supernatants were harvested after an additional 1 hour and assayed for IL- ⁇ production by ELISA. Data are representative of three independent experiments.
• MDSC p 0.0006.
• E Histograms represent % divided CFSE-labeled responding T cells when plated against recovered wild-type or ASC _/" MDSC-IL13 from day 5 post-transplant at a ratio of 1 : 1 and harvested on day 3. Significant p values ( ⁇ 0.05) were found when comparing any single group to wild-type MDSC-IL13 recovered from GvHD mice.
• FIG. 4 Inflammasome induction in MDSC associated with loss of Argl expression MDSC-IL13 were induced for LRP3 or AIM2 inflammasomes as indicated, washed
• YFP-Argl bone marrow indicates baseline YFP fluorescence.
• F IL- ⁇ production before and after LRP3 (ATP+LPS) inflammasome activation for bulk MDSC-IL13 or sorted granulocytic Ly6G+C+ (Ly6G+) and monocytic Ly6C+ subsets.
• G CFSE proliferation of anti-CD38 driven CD8+ B6 T cell responses in the presence of sorted granulocytic (Ly6G+) or monocytic (Ly6C+) subsets of MDSC-IL 13 at a 1 : 1 ratio.
• FIG. 5 Inflammasome induction in human MDSC interferes with their suppressor function.
• Human MDSC were generated from donor PBMC.
• B Representative histograms of CellTrace Violet (Life Technologies, Carlsbad, CA) labeled responder PBMC in presence of cultured human MDSCs from unrelated donors indicated by solid line. Dotted line indicates no MDSC proliferation control, gray histogram indicates PBMC alone (no CD3s or MDSC).
• Stim represents the allo-response against MDSC with no anti-CD38.
• Stim indicates addition of anti-CD38 microbeads (2: 1) + IL-2 (100 U/ml) to demonstrate MDSC suppression of T cell activation.
• Tx'd indicates MDSC have been treated for inflammasome activation prior to plating with anti-CD38 microbeads + IL-2.
• C Aggregate data show percent division of responding CD8 and CD4 T cells. Data represent responses from three unrelated PBMC donors, and is representative of two independent experiments.
• FIG. 7. CD45.2+ MDSC-IL13 recovery.
• A Representative flow plot showing CD45.2 + frequencies of pooled splenocytes before and after enrichment. Bottom graphs represent gated cells indicated in top graph (CD45.2+ CD45.1-ve)
• FIG. 8 High dose MDSC-IL13.
• Kaplan-Meier survival graph showing effect of increased MDSC-IL13 day 0 doses in model of GvHD.
• data already shown in FIG. IF is indicated by a dotted line and slightly smaller symbols.
• FIG. 9. MDSC-IL13 day 0 infusion phenotype. Surface expression of indicated markers for wild-type B6 (shaded) and ASC ko (bold) MDSC-IL13 on harvest day (day +4 culture) prior to infusion. Data are representative of at least three independent experiments.
• FIG. 10 ASC-dependent inflammasome induced loss of suppression for CD4 responder T cells.
• wild-type (wt) or ASC ko MDSC-IL13 were treated as indicated, and washed extensively then applied to a CFSE T cell proliferation assay at a 1 : 1 ratio. Shown are representative plots of gated CD4+ responder T cells, from two independent experiments. DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
• This disclosure describes, in one aspect, a method of improving the use of myeloid- derived suppressor cells (MDSCs) for inhibiting graft-versus-host disease (GvHD).
• MDSCs myeloid- derived suppressor cells
• GvHD graft-versus-host disease
• Myeloid-derived suppressor cells are a naturally-occurring immune regulatory population involved in inhibiting ongoing inflammatory responses.
• In vitro MDSC generation from bone marrow can enhance survival in an acute model of lethal graft-versus-host disease (GvHD).
• Donor MDSC infusion only partially ameliorates GvHD lethality, however.
• this disclosure describes an investigation of the fate of MDSC after transfer in the setting of acute GvHD (aGvHD).
• aGvHD acute GvHD
• MDSC transferred to lethally-irradiated recipients of allogeneic donor hematopoietic grafts are exposed to an intense inflammatory environment associated with aGvHD, which can directly undermine the suppressive capacity of the MDSCs.
• MDSC Under GvHD inflammatory conditions, MDSC can lose suppressor function and, therefore, their potential to inhibit GvHD lethality. Even brief in vitro exposure to inflammasome-activating mediators can negate the suppressive potential of cultured murine and human-derived MDSCs. Consistent with a role for the inflammasome, donor MDSCs deficient in the adaptor ASC (Apoptosis-associated speck-like protein containing a CARD) that assembles inflammasome complexes conferred improved survival of mice developing GvHD compared to wild-type donor MDSC. These data suggest the use of MDSC as a therapeutic approach for inhibiting GvHD and other systemic inflammatory conditions can be more effective when combined with approaches that limit in vivo MDSC inflammasome activation, thereby empowering MDSCs to maintain their suppressive potential.
• adaptor ASC Apoptosis-associated speck-like protein containing a CARD
• hematopoietic cell transplantation is a potentially curative therapy for a variety of hematologic diseases including leukemias and lymphomas.
• aHCT allogeneic hematopoietic cell transplantation
• GvHD graft-vs-host disease
• Targeted cellular immunotherapy as an adjunct to aHCT can control GvHD while also reducing side effects associated with conditioning regimens by being highly targeted and internally self-regulating.
• MDSC Myeloid-derived suppressor cells
• BM bone marrow
• growth factor release e.g., GM-CSF, G-CSF
• MDSCs can suppress systemic immune pathology via unique mechanisms including local amino acid deprivation, nitric oxide, prostaglandin E2, anti -inflammatory cytokines, reactive oxygen species, as well as promotion of regulatory T cells (Tregs).
• Bone marrow-derived cultures of MDSCs incubated with interleukin-13 (IL-13) suppress aGvHD via an arginase 1- dependent depletion of L-arginine, which in turn inhibits allogenic T cell responses.
• IL-13 interleukin-13
• Acute GvHD (aGVHD) is often described as having three phases: transplant
• the conditioning regimen and the rapid priming of a high frequency of allo-specific donor T cells lead to intense systemic inflammation. Since aGvHD expands donor T cells that have the capacity to attack the recipient, an effective approach to inhibit lethality involves dampening T cell responses early post-transplant, when inflammation is mounting and alloreactive T cells are contributing to organ injury, amplifying the inflammatory response. Thus, for donor MDSC to provide effective therapy, these cells must remain viable and function for a sufficiently long period of time to impede alloreactive T cell priming and expansion.
• the inflammasome is a multi-molecular complex that acts as a downstream component of innate immune sensing pathways.
• Factors associated with inflammasome activation include, for example, gut-associated leakage of bacterial products and danger-associated molecules (DAMPs) from dead and dying cells.
• DAMPs danger-associated molecules
• ASC adaptor protein ASC
• Apoptosis-associated speck-like protein containing a CARD Apoptosis-associated speck-like protein containing a CARD
• pro-caspase-1 autocatalytic cleavage, and ultimately cleavage and export of active IL- 1 ⁇ or IL-18.
• Molecules involved in the different inflammasomes vary depending on the source of activating signals and the upstream molecule that coalesces with ASC.
• AFM2-like receptor (ALR) family inflammasomes can be initiated by binding cytosolic dsDNA to AIM2
• LRP3 (absent in myeloma 2), while the LRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome is activated by microbial and host danger signals, and changes in extracellular ATP content.
• MDSCs were generated from cultured fresh bone marrow (BM) with cytokine growth factors GM-CSF and G-CSF in four days. Activation of cultured MDSCs 24 hours prior to harvest with IL-4 or IL-13 stimulates expression of arginase-1 and promotes functional suppression of T cells both in vitro and in the context of GvHD.
• IL-4 or IL-13 stimulates expression of arginase-1 and promotes functional suppression of T cells both in vitro and in the context of GvHD.
• T cells induce aGvEfD resulting in a mean survival time of 24.5 days.
• animals receiving MDSC-IL13 therapy had extended survival to 47.5 days (FIG. 1 A).
• a majority of treated animals succumbed to GvHD-induced death by day 100, suggesting pathology was reduced or delayed, but not eliminated.
• bone marrow or bone marrow plus T cell (GvHD conditions) with congenic CD45.2 + MDSC-IL13s were given to CD45.1 + animals that were then sacrificed at day 5 post-transplant to examine the phenotype and function of recovered MDSCs.
• MDSCs recovered from transplanted animals receiving only conditioning plus bone marrow maintained an immature CD1 lc l0 , MHCII 10 , F4/80 int appearance (FIG. IB and FIG. 1C).
• MDSC-IL13s transferred to animals undergoing aGvHD conditions (CD8 + CD4 + T cells, CD25-) upregulated CD1 lc and MHC class II, hallmarks of activated myeloid cells.
• F4/80 expression was also increased, suggesting activation and differentiation occurred rapidly in response to the ongoing inflammatory environment promoted by allo-reactive T cells (FIG. IB and FIG. 1C). Other markers of co-stimulation and activation remained unchanged (FIG. 6).
• MDSC-IL13s from day 5 animals transplanted with bone marrow only were highly suppressive (FIG. ID, No GvHD).
• T cell responses in the presence of MDSC-IL13s recovered from GvHD animals showed only a slight reduction in overall proliferation relative to the no MDSC control group (FIG. ID), indicating a loss of suppressor cell function of MDSCs in GvHD recipients.
• One explanation for the loss of suppression by MDSCs in vivo could be compromised survival of the suppressive cells.
• MDSC viability is maintained by continuous suppression of the extrinsic caspase-8 and intrinsic mitochondrial death pathways. Manipulating either of these pathways can cause a rapid decline in MDSC viability and a concomitant decrease in
• IL- ⁇ can directly interfere with Treg-mediated suppression and promotion of T effector function.
• LRP3 and AIM2 represent two major families of inflammasomes in which a variety of signals can potentiate the inflammasome cascade, but the adaptor protein ASC may be a common component required for full activation of the inflammasome.
• Wild-type and ASC _/" ⁇ Pycard 1' ) bone marrow were used to generate MDSC-IL13s to test whether they could be induced for inflammasome activity.
• ASC _/" MDSC-IL13s had a similar surface phenotype to wild-type MDSC-IL13s (FIG. 9).
• the LRP3 inflammasome was tested by incubating MDSC-IL13s with LPS for three hours followed by ATP, while the AEVI2 inflammasome was engaged using LPS followed by poly(dT) transfection. In as little as one hour after the secondary stimulus, IL- ⁇ was detected in culture supernatants from wild-type MDSC-IL13s (FIG. 3A).
• ASC _/_ MDSC-IL13s produced no detectable IL- ⁇ , establishing that MDSC-IL13s are capable of rapidly responding to changes in their environment to produce the pro-inflammatory mediator IL- ⁇ in an ASC- dependent fashion.
• inflammasome induction of MDSC-IL13s can alter their suppressive capacity. Following the same procedure to induce inflammasomes in just four hours, MDSC-IL13s were then washed extensively and plated in an in vitro suppression assay of T cell proliferation to anti-CD38 stimulation. In vitro inflammasome induction reduces the ability of MDSC-IL13s to functionally suppress responding CD8 + (FIG. 3B) and CD4 + (FIG. 10) T cells. Furthermore, this effect was also dependent on ASC, supporting the hypothesis that inflammasome activation is associated with a loss of suppressive function rather than, for example, compromised viability and/or other maturation factors.
• the mechanism for MDSC-IL13-mediated suppression of GvHD is arginase-1 (argl) activity that directly undermines T cell responsiveness and promotes GvHD survival.
• argl arginase-1
• the bio- activity of argl enzyme from MDSC-IL13s after inflammasome induction was measured to determine whether argl activity was reduced in concert with inflammasome induction.
• a marked drop in argl activity as measured by either mRNA (not shown) or bio-enzymatic activity was found when either LRP3 or AEVI2 inflammasomes were induced (FIG. 4A and FIG. 4B).
• a similar drop was not evident in ASC _/" MDSCs, though there was a trend, suggesting that the pathways may not be directly linked.
• YFP-Argl transgenic animals (YARG, in which argl expression is linked to yellow fluorescence protein (YFP)) were used, allowing one to quickly assay for an associated loss of expression.
• IL-13 readily upregulates YFP fluorescence, while ⁇ (which induces iNOS-expressing MDSCs) did not increase YFP fluorescence (FIG. 4 C and FIG. 4D).
• inflammasome induction via LRP3 or AIM2 pathways resulted in a concomitant loss of YFP fluorescence, indicating that argl expression had been arrested in association with inflammasome inducing conditions.
• MDSC-IL13s generated from YARG transgenic animals were applied to the transplant model, given either bone marrow only or bone marrow plus whole T cells for GvFID conditions.
• YFP fluorescence from MDSC recovered after five days from bone marrow only animals was reduced relative to expression immediately after culture, but still readily detected above background (FIG. 4E).
• YFP was no longer detectable, being reduced to background levels seen in un-stimulated bone marrow.
• MDSCs are often defined as heterogeneous, with two major subsets described in murine systems being granulocytic (Ly6G + ) and monocytic (Ly6C + G " ). Each subset was evaluated to determine whether each had a similar capacity for inflammasome activation and how suppressor capacity might be differentially affected.
• MDSC-IL13s from cultured bone marrow are >90% Ly6C+ (FIG. 9), and were sorted based on Ly6G expression. LRP3 inflammasome activating conditions lead to equivalent levels of ILip production for both Ly6C + G " monocytic and Ly6G + granulocytic subsets (FIG. 4F).
• MDSCs were generated from human peripheral blood mononuclear cells (PBMCs) as previously described (Lechner et al., 2010, J Immunol 185(4):2273-2284). These MDSCs were used to investigate whether human MDSCs might have a similar pre-disposition towards PBMCs.
• PBMCs peripheral blood mononuclear cells
• inflammasome-activated loss of function as found with murine MDSCs.
• Human PBMCs enriched for the myeloid marker CD33, were cultured for seven days with GM-CSF and IL-6. Under these conditions, human MDSCs suppressed anti-CD38 mAb-driven proliferation of unrelated PBMCs responders.
• Human MDSCs were confirmed as capable of responding to inflammasome activating conditions, by adding LPS followed by ATP to engage the LRP3 inflammasome. Both LPS and ATP are needed to drive MDSC production of IL- ⁇ (FIG. 4A). Next, inflammasome-activated MDSC were added to anti-CD38 mAb-driven PBMC
• allo-reactive T cells are a contributing factor to morbidity and mortality in clinical GvHD, and the use of regulatory cell therapy can be a viable strategy to control them.
• MDSCs can be generated from normal bone marrow in a relatively short amount of time and can effectively suppress GvHD, autoimmunity, and allo-graft rejection.
• This disclosure reports that MDSCs activated by the cytokine IL-13 produce argl that, in turn, allows the MDSCs to suppress GvHD.
• cytokine IL-13 produce argl that, in turn, allows the MDSCs to suppress GvHD.
• a stringent GvHD model with full MHC mismatching MDSC therapy promotes extended survival but fails to ultimately protect a majority of animals from lethal GvHD.
• inflammasome activation when inflammasome activation is genetically prohibited using ASC _/" MDSC- IL13s, GvHD survival is improved over wild-type MDSC-IL13 transplant recipients and recovered ASC _/" MDSC-IL13s maintain better ex vivo suppressive capacity.
• Additional methods to alter MDSC susceptibility to inflammasome activation/conversion can include genetic knockdown of ASC or other inflammasome associated genes (e.g., NLRP3, AIM2, Caspase-1).
• the genetic knockdowns can be obtained using, for example, sh/siRNA, TALEN, meganuclease, megaTALENs, and/or CRISPER technologies, and/or site directed mutagenesis.
• Myeloid cells are involved in initiating and shaping immune responses in both proinflammatory and anti-inflammatory directions, and demonstrate remarkable plasticity. This adaptability may be both a curse and a curse, in that it allows one to rapidly generate highly suppressive cells from normal bone marrow in vitro, yet permits the transient efficacy seen upon transfer to a severe inflammatory environment such as aGvHD. While MDSCs are described as heterogeneous in nature and phenotypic markers don't always translate between disease models or species, inflammasome activation pathways appear to be highly conserved. In the data reported in this disclosure, MDSCs generated from mouse bone marrow or human PBMCs readily activate inflammasomes resulting in IL- ⁇ production that correlates to a loss of suppressor function. Patients with aGvHD can exhibit cleaved caspase-1 and increased IL- ⁇ , further supporting the conclusion that GvHD is associated with inflammasome activation.
• MDSCs are nearly ubiquitously associated with established tumors and can actively perturb immune therapy interventions.
• One distinction between tumor-induced and GvHD-induced inflammasome activation of MDSCs is that tumor-associated MDSC development occurs in the setting of chronic localized inflammation, in contrast to the intense, systemic inflammatory response of GvHD.
• GVHD-activated MDSCs secrete IL- ⁇
• IL- ⁇ has pleiotropic effects dependent on the cell producing it, the state of the surrounding microenvironment, and temporal expression, but is generally understood to be pro-inflammatory and in some instances counter-regulatory.
• MDSC-IL13 cells recovered from day +5 GvHD transplant recipients are applied to an in vitro suppression assay, the proportion of T cells proliferating were not different than controls with no MDSCs, although proliferating T cells underwent fewer cell divisions, suggesting some suppressive capacity remained.
• LRP3 inflammasome activation in the context of GvHD has been demonstrated for both radiotherapy and chemotherapy induction protocols, resulting in tissue damage and release of danger- associated molecular patterns (DAMPs).
• DAMPs danger- associated molecular patterns
• Adoptively transferred MDSCs also can be susceptible to inflammasome induction, and the same mediators may contribute to in vivo activation.
• Reagents that selectively target the LRP3 inflammasome may promote dual purposes of inhibiting inflammasome activation in the host and infused donor MDSCs. For example,
• MCC950 a small molecule inhibitor
• BFIB ⁇ -hydroxybutyrate
• LRP3 -mediated diseases LRP3 -mediated diseases.
• viral and bacterial products, such as dsDNA also can be potent drivers of both GvFID and of the AIM2-like receptor family of inflammasomes. While GvFID development is not dependent on host MyD88/TRIF pathway activity, the release of dsDNA by dead/dying cells from radiation and GvFID-induced injury may amplify lethality under some conditions.
• Pre-treatment of therapeutic MDSC cellular therapy to specifically inhibit inflammasome activation via genetic alteration e.g., gene expression knockdown, sh/siRNA/meganuclease, megaTALs, CRISPER
• pharmacologic inhibition MCC950/BHB
• pharmacologic treatment or MDSC- specific targeting in vivo to deliver drugs and agents that can regulate inflammasome formation or function or agents that regulate inciting factors in the patient that lead to inflammasome activation of the patient (prior to, during, and/or after transplant) also can reduce inflammasome conversion of MDSC cell therapy with the added benefit of preventing host-derived
• inflammasome activity which has been shown to be associated with increased severity of GvHD.
• a novel approach to reversing MDSC suppression in tumors can involve activating MDSCs within the tumor using approaches such as, for example, providing an inciting agent such as, for example, uric acid, ATP, agents that stimulate Toll-like receptors, DNA, RNA, and/or other agents that can upregulate inflammasome function.
• an inciting agent such as, for example, uric acid, ATP, agents that stimulate Toll-like receptors, DNA, RNA, and/or other agents that can upregulate inflammasome function.
• this disclosure describes a method of treating a subject having or at risk of having graft-versus host disease (GvHD).
• the method includes administering to the subject a plurality of MDSCs in an amount effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject.
• the term “treat” or variations thereof refer to reducing, limiting progression, ameliorating, or resolving, to any extent, the symptoms or clinical signs related to GvHD.
• a “treatment” may be therapeutic or prophylactic.
• “Therapeutic” and variations thereof refer to a treatment that ameliorates one or more existing symptoms or clinical signs associated with GvHD.
• “Prophylactic” and variations thereof refer to a treatment that limits, to any extent, the development and/or appearance of a symptom or clinical sign of GvHD.
• a “therapeutic” treatment is initiated after GvHD manifests in a subject, while “prophylactic” treatment is initiated before GvHD manifests in a subject.
• “symptom” refers to any subjective evidence of GvHD
• “sign” or “clinical sign” refers to an objective physical finding relating to GvHD capable of being found by one other than the patient.
• a subject “at risk” for developing GvHD is a subject that possesses one or more indicia of increased risk of having, or developing, GvHD compared to individuals who lack the one or more indicia, regardless of the whether the subject manifests any symptom or clinical sign of having or developing GvHD.
• the method can include repeated administrations of MDSCs to replace MDSCs in previous administrations as the previously-administered MDSCs experience inflammasome activation and become less able to suppress alloreactive T cells. That is, sequentially re-administering MDSCs can replenish a population of MDSCs that lose suppression in an inflammatory environment with new MDSCs that have not yet activated their inflammasome function.
• the therapy can include a minimum of at least two administrations of MDSCs such as, for example, at least three administrations, at least five administrations, at least ten administrations, at least fifteen administrations, at least twenty administrations, at least twenty-five administrations, or at least fifty administrations.
• the therapy can include a maximum of no more than fifty administrations of MDSCs such as, for example, no more than forty administrations, no more than thirty administrations, no more than twenty administrations, no more than ten administrations, or no more than five administrations.
• the therapy can include a range of administrations having endpoints defined by any minimum number of administrations listed above and any maximum number of
• the therapy can include from three to five administrations of MDSCs.
• sequential administrations of MDSCs can be separated by a minimum interval of at least 24 hours such as, for example, at least two days, at least three days, at least seven days, at least 14 days, at least 30 days, or at least 90 days.
• sequential administrations of MDSCs can be separated by a maximum interval of no more than one year, no more than six months, no more than 90 days, no more than 60 days, no more than 30 days, or no more than 14 days.
• sequential administrations of MDSCs can be separated by an interval characterized as a range having endpoints defined by any minimum interval between administrations listed above and any maximum interval between administrations listed above that is greater than the minimum interval between administrations.
• the therapy can include MDSCs administered at an interval having a minimum of once per day to a maximum of once every other day.
• the MDSCs can be treated and/or include a genetic modification that causes the MDSCs to resist inflammasome activation.
• the MDSCs can be pre-treated with, for example, a drug, sh/siRNA, and/or CRISPRs that causes the MDSCs to resist inflammasome activation.
• An exemplary genetic modification that causes the MDSCs to resist inflammasome activation can include a deficiency in apoptosis-associated speck-like protein containing a CARD (ASC).
• a similar effect can be achieved in some embodiments by further treating the subject during and/or after MDSC infusion with an agent that inhibits the inflammasome and thereby reduce the extent to which the infused MDSCs are subjected to inflammasome activation.
• Exemplary approaches for inhibiting the inflammasome can include agents that directly inhibit the inflammasome. Other approaches can involve using an agent that targets and/or at least partially neutralizes an inflammasome inciting agent.
• Exemplary inflammasome inciting agents include, for example, uric acid, ATP, an agent that stimulates a Toll-like receptor, DNA, RNA, and/or other agent that can upregulate inflammasome function.
• the therapy can be administered for a minimum duration of at least one week such as, for example, at least two weeks, at least one month, at least three months, at least six months, or at least one year.
• the therapy can be administered for a maximum duration of no more than 20 years such as, for example, no more than 10 years, no more than five years, no more than two years, no more than one year, no more than nine months, no more than six months, no more than three months, no more than two months, no more than one month, or no more than two weeks.
• the therapy can be administered for a duration characterized as a range having as endpoints any minimum duration listed above and any maximum duration listed above that is greater than the minimum duration.
• the therapy can have a duration of from one week to two weeks.
• the MDSCs can be formulated into a pharmaceutical composition that includes a pharmaceutically acceptable carrier.
• carrier includes any solvent, dispersion medium, vehicle, coating, diluent, antibacterial, and/or antifungal agent, isotonic agent, absorption delaying agent, buffer, carrier solution, suspension, colloid, and the like.
• carrier includes any solvent, dispersion medium, vehicle, coating, diluent, antibacterial, and/or antifungal agent, isotonic agent, absorption delaying agent, buffer, carrier solution, suspension, colloid, and the like.
• the use of such media and/or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
• pharmaceutically acceptable refers to a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the MDSCs without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
• compositions may be formulated in a variety of forms adapted to a preferred route of administration.
• a composition can be administered via known routes including, for example, parenteral (e.g., intradermal, transcutaneous, subcutaneous,
• intramuscular, intravenous, intraperitoneal, etc. routes of administration.
• MDSCs may be provided in any suitable form including but not limited to a solution, a suspension, an emulsion, or any form of mixture.
• the composition may be delivered in formulation with any pharmaceutically acceptable excipient, carrier, or vehicle.
• a formulation may be conveniently presented in unit dosage form and may be prepared by methods well known in the art of pharmacy.
• Methods of preparing a composition with a pharmaceutically acceptable carrier include the step of bringing the MDSCs into association with a carrier that constitutes one or more accessory ingredients.
• a formulation may be prepared by uniformly and/or intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.
• the amount of MDSCs administered can vary depending on various factors including, but not limited to, the weight, physical condition, and/or age of the subject, and/or the route of administration.
• the absolute amount of MDSCs included in a given unit dosage form can vary widely, and depends upon factors such as the species, age, weight and physical condition of the subject, and/or the method of administration. Accordingly, it is not practical to set forth generally the amount that constitutes an amount of MDSCs effective for all possible applications. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
• a single administration of MDSCs can include a minimum of at least 10 5 MDSCs such as, for example, at least 10 6 MDSCs, at least 10 7 MDSCs, at least 10 8 MDSCs, at least 10 9 MDSCs, at least 10 10 MDSCs, at least 10 11 MDSCs, or at least 10 12
• a single administration of MDSCs can include a maximum of no more than 10 13 MDSCs such as, for example, no more than 10 12 MDSCs, no more than 10 11 MDSCs, no more than 10 10 MDSCs, no more than 10 9 MDSCs, no more than 10 8 MDSCs, no more than 10 7 MDSCs, or no more than 10 6 MDSCs.
• a single administration of MDSCs can include a number of MDSCs characterized as a range having endpoints defined by any minimum number of MDSCs listed above and any maximum number of MDSCs listed above that is greater than the minimum number of MDSCs.
• a single administration of MDSCs can include a range of 10 7 MDSCs to 10 10 MDSCs.
• a single administration of MDSCs can include a range of 4 10 7 MDSCs to 5 10 8 MDSCs.
• this disclosure describes a method of treating a tumor.
• the method includes increasing inflammasome activation of MDSCs sufficiently to disable the suppressor function of the MDSCs in the vicinity of the tumor.
• increasing inflammasome activation can include providing at least one inflammasome inciting agent such as, for example, uric acid, ATP, an agent that stimulates a Toll-like receptor, DNA, RNA, and/or other agent that can upregulate inflammasome function.
• the inflammasome inciting agent can be co-administered with a conventional anti-tumor therapy designed to eradicate the tumor such as, for example, chemotherapy, radiation therapy, surgery, and/or immune therapy with drugs, antibodies/proteins, vaccines, and/or cell therapies.
• a conventional anti-tumor therapy designed to eradicate the tumor
• co-administered refers to two or more components of a combination administered so that the therapeutic or prophylactic effects of the combination can be greater than the therapeutic or prophylactic effects of either component administered alone. Two components may be co-administered simultaneously or sequentially. Simultaneously co- administered components may be provided in one or more pharmaceutical compositions.
• Sequential co-administration of two or more components includes cases in which the
• ком ⁇ онентs are administered so that each component can be present at the treatment site at the same time.
• sequential co-administration of two components can include cases in which at least one component has been cleared from a treatment site, but at least one cellular effect of administering the component (e.g., cytokine production, activation of a certain cell population, etc.) persists at the treatment site until one or more additional components are administered to the treatment site.
• a co-administered combination can, in certain circumstances, include components that never exist in a chemical mixture with one another.
• the anti-tumor therapy may be administered at the same dose and frequency for which the therapy has received regulatory approval. In other cases, the anti -tumor therapy may be administered at the same dose and frequency at which it is being evaluated in clinical or preclinical studies.
• the inflammasome inciting agent may be formulated in any suitable form.
• the inflammasome inciting agent may be administered at the same dose and frequency for which it may have received regulatory approval.
• the inflammasome inciting agent may be administered at the same dose and frequency at which it may be being evaluated in clinical or preclinical studies.
• the term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements; the terms “comprises,” “comprising,” and variations thereof are to be construed as open ended— i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, "a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one; and the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
• the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.
• mice 6-8 wk-old female BALB/c (H2 d ), C57BL/6NCr (H2 b ) and B6-Ly5.2/Cr (B6-CD45.1 + , H2 b ) mice were purchased from the National Cancer Institute.
• ASC knockout mice (Mariathasan et al., 2004. Nature 430(6996):213-218) and YFP-Argl (YARG) mice (Reese et al., 2007.
• mice were bred and housed in a specific pathogen-free facility in micro-isolator cages in protocols approved by the Institutional Animal Care and Use Committee at the University of Minnesota.
• Murine MDSC were generated by culturing C57B1/6 bone marrow at 3 x 10 5 cells/mL in Dulbecco modified Eagle medium plus 10% fetal calf serum, 50 ⁇ 2-mercaptoethanal, 10 mM HEPES, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, and
• supplemental amino acids 1.5 of each of mM L-glutamine, L-arginine, and L-asparagine.
• MDSC were harvested on day 4 by gently removing 70% of the culture supernatant. The remaining media and loosely adherent cells were then collected prior to addition of Trypsin/EDTA. After 10 minutes at 37°C, plates were lightly scraped and washed to collect remaining cells, which when pooled with lightly adherent cells resulting in >92% CD1 lb + recovery. For inflammasome induction, on day 4 LPS (0.2 ⁇ g/ml) was added to cultures.
• Human MDSC were generated from normal donor PBMC, isolated from adult blood obtained from Memorial Blood Center (Minneapolis, MN) by centrifugation using a Histopaque gradient (Sigma-Aldrich, St. Louis, MO). In vitro generation was carried out as previously described (Lechner et al., 2010. J Immunol 185(4):2273-2284), modified by prior CD33 + myeloid enrichment, which was carried out using Miltenyi MACs system according to instructions. Cultures were harvested on day 7 for inflammasome induction, followed by washing and plating in suppression assays as previously described (Hippen et al., 2008. Blood 112(7):2847-2857). Human blood bank samples were obtained via guidelines approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota.
• BALB/c recipients were lethally irradiated using 700cGy total body irradiation one day prior to infusion of 1 x 10 7 C57B1/6 donor bone marrow, 2 x 10 6 lymph node purified C57B1/6 CD25-depleted T cells, and 6 10 6 cultured C57B1/6 MDSC-IL13 on day 0 or as indicated.
• T cell enrichment was carried out using a negative cell isolation system (EASYSEP, Stemcell Technologies Inc., Vancouver, Canada) and biotinylated antibodies to CD 19, B220, CD1 lb, CD1 lc, K1.1, ⁇ TCR and CD25 according to the manufacturer's instructions. Mice were monitored daily for survival.
• CD45.2 + (MDSC-IL13) splenocytes were isolated by depletion of host and donor T cells using the RAPID SPHERE EASYSEP method (Stemcell Technologies Inc., Vancouver, Canada) and anti-CD45.1 -biotinylated antibody according to the manufacturer's instructions, resulting in >80% CD45.2+ MDSC-IL13 recovery (FIG. 7).
• MDSC-IL13 cultures were bulk labeled with APC-conjugated anti-Ly6G (clone 1A8) antibodies, followed by anti-APC microbead labeling and application to Miltenyi MACs LS columns for separation based on Ly6G+ expression according to manufacturer instructions. This resulted in effective sorting of granulocytic and monocytic subsets that were then used for further analysis.
• Flow cytometric data acquisition was carried out on a BD LSRFortessa and analysis was done using FlowJo software (FlowJo, LLC, Ashland. OR).
• FlowJo software FlowJo, LLC, Ashland. OR.
• responding T cells were stained with 3.5 ⁇ carboxyfluorescein succinimidyl ester (CFSE) and incubated with 0.25 ⁇ g/ml anti-CD38 before analysis on day 3.
• CFSE carboxyfluorescein succinimidyl ester
• responder PBMCs were labeled with CELL TRACE Violet (ThermoFisher Scientific, Waltham, MA) and stimulated with anti-CD38 mAb-coated beads (DYNAL, Thermo Fisher Scientific, Waltham, MA; 2: 1 ratio) plus 100 U/ml huIL-2; samples were collected on day 4.
• CELL TRACE Violet ThermoFisher Scientific, Waltham, MA
• anti-CD38 mAb-coated beads DYNAL, Thermo Fisher Scientific, Waltham, MA; 2: 1 ratio
• Murine and human IL- ⁇ in culture supernatants was assessed using respective BD OptEIA ELISA sets, following manufacturer's instructions (BD Biosciences, San Jose, CA).
• BD Biosciences San Jose, CA
• For western blots purified MDSC were washed and resuspended in lysis buffer containing RIP A, protease (Santa Cruz Biotechnology, Inc., Dallas, TX) and phosphatase (Sigma- Aldrich, St, Louis, MO) inhibitor cocktail then snap frozen. 4 ⁇ g of protein from cell lysates were
• Arginase- 1 activity was determined using QuantiChrom Arginase Assay Kit (Bioassay Systems LLC, Hayward, CA). Samples were normalized to 4 ⁇ 10 5 cells per sample, washed, pelleted and resuspended in 100 ⁇ of protease inhibitor-containing lyse buffer then assayed according to manufacturer instructions. Statistical analysis

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Wood Science & Technology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Hematology (AREA)
• Cell Biology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Transplantation (AREA)
• Gastroenterology & Hepatology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Mycology (AREA)
• Physics & Mathematics (AREA)
• Toxicology (AREA)
• Plant Pathology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Developmental Biology & Embryology (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=56686964

Family Applications (1)

Country Status (9)

Families Citing this family (4)

Citations (1)

Family Cites Families (13)

• 2016
  • 2016-08-05 EP EP20153949.1A patent/EP3682889B1/en active Active
  • 2016-08-05 JP JP2018506141A patent/JP6927499B2/ja active Active
  • 2016-08-05 CN CN201680046264.8A patent/CN108883131B/zh active Active
  • 2016-08-05 PT PT201539491T patent/PT3682889T/pt unknown
  • 2016-08-05 AU AU2016303622A patent/AU2016303622B2/en not_active Ceased
  • 2016-08-05 EP EP16751781.2A patent/EP3331538B1/en active Active
  • 2016-08-05 EP EP22215685.3A patent/EP4218776A3/en not_active Withdrawn
  • 2016-08-05 WO PCT/US2016/045739 patent/WO2017024213A1/en not_active Ceased
  • 2016-08-05 CN CN202210388064.8A patent/CN114790447A/zh active Pending
  • 2016-08-05 CA CA2993806A patent/CA2993806A1/en active Pending
  • 2016-08-05 ES ES16751781T patent/ES2789574T3/es active Active
  • 2016-08-05 US US15/747,902 patent/US10894061B2/en active Active
  • 2016-08-05 ES ES20153949T patent/ES2939534T3/es active Active
• 2020
  • 2020-12-11 US US17/119,832 patent/US12234480B2/en active Active
• 2021
  • 2021-07-19 JP JP2021118749A patent/JP7235259B2/ja active Active
• 2022
  • 2022-09-09 AU AU2022228188A patent/AU2022228188A1/en not_active Abandoned
• 2023
  • 2023-02-15 JP JP2023021455A patent/JP2023053338A/ja active Pending

Patent Citations (1)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events